Who are Magnesium sulphate.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Magnesium sulfate 33% solution, Magnesium Sulfate Infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/magnesium-sulphate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Magnesium sulphate. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Magnesium sulphate. (Magnesium sulphate.) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Electrolyte supplement / anticonvulsant / tocolytic agent. Area: Obstetrics, Neurology, Gastroenterology, Emergency Medicine.

marketed Electrolyte supplement / anticonvulsant / tocolytic agent Voltage-gated calcium channels, NMDA receptor Obstetrics, Neurology, Gastroenterology, Emergency Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Magnesium sulphate. (Magnesium sulphate.) — Ain Shams University. Magnesium sulphate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuromuscular excitability and vascular smooth muscle contractility.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Magnesium sulphate. TARGET	Magnesium sulphate.	Ain Shams University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	Voltage-gated calcium channels, NMDA receptor
Magnesium sulfate 33% solution	Magnesium sulfate 33% solution	The Baruch Padeh Medical Center, Poriya	marketed	Electrolyte supplement / anticonvulsant	Voltage-gated calcium channels, NMDA receptors
Magnesium Sulfate Infusion	Magnesium Sulfate Infusion	Ondokuz Mayıs University	marketed	Electrolyte supplement / anticonvulsant / tocolytic agent	NMDA receptor antagonist; calcium channel modulator

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Electrolyte supplement / anticonvulsant / tocolytic agent class)

Ain Shams University · 1 drug in this class
Ondokuz Mayıs University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Magnesium sulphate. — Competitive Intelligence Brief. https://druglandscape.com/ci/magnesium-sulphate. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing